COVID-19: Canadian company testing vaccine candidates that target variant strains
April 13, 2021
Source: Vancouverisawesome.com
A Canadian company has announced that it is doing preclinical studies of unique COVID-19 vaccine candidates to target variant strains.
Eyam Vaccines and Immunotherapeutics (EYAM) announced Monday (April 12) that it is beginning preclinical studies to test the efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants, explains a news release.
The preclinical testing begins to address the “urgent societal need to accelerate containment of the emerging SARS-CoV-2 variants.”
In November 2020, EYAM entered into a licensing agreement with the University of British Columbia (UBC) in Vancouver to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform.
The Canadian company says it “anticipates rapid advancement” for these COVID-19 vaccine candidates, crediting its “platform and strategy,” as well as the collaborative research agreement with the University of British Columbia, which “differentiates the potential vaccine product from other vaccines that have already come to market.”
When asked how the EYAM’s vaccine technology targets several variant strains, Chief Executive Officer Ryan M. Thomas tells Vancouver Is Awesome that the next-generation mRNA vaccine technology is “robust, with several proprietary advancements over the first generation of mRNA vaccines.”
Thomas says the company’s vaccine platform will target the major COVID-19 strains including the “Wuhan, South Africa, Brazil, UK (Kent) and California variants.”
Full story: https://www.vancouverisawesome.com/coronavirus-covid-19-local-news/covid-19-canadian-company-testing-vaccine-candidates-that-target-variant-strains-3628843
COVID-19: Canadian company testing vaccine candidates that target variant strains
April 13, 2021
Source: Vancouverisawesome.com
A Canadian company has announced that it is doing preclinical studies of unique COVID-19 vaccine candidates to target variant strains.
Eyam Vaccines and Immunotherapeutics (EYAM) announced Monday (April 12) that it is beginning preclinical studies to test the efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants, explains a news release.
The preclinical testing begins to address the “urgent societal need to accelerate containment of the emerging SARS-CoV-2 variants.”
In November 2020, EYAM entered into a licensing agreement with the University of British Columbia (UBC) in Vancouver to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform.
The Canadian company says it “anticipates rapid advancement” for these COVID-19 vaccine candidates, crediting its “platform and strategy,” as well as the collaborative research agreement with the University of British Columbia, which “differentiates the potential vaccine product from other vaccines that have already come to market.”
When asked how the EYAM’s vaccine technology targets several variant strains, Chief Executive Officer Ryan M. Thomas tells Vancouver Is Awesome that the next-generation mRNA vaccine technology is “robust, with several proprietary advancements over the first generation of mRNA vaccines.”
Thomas says the company’s vaccine platform will target the major COVID-19 strains including the “Wuhan, South Africa, Brazil, UK (Kent) and California variants.”
Full story: https://www.vancouverisawesome.com/coronavirus-covid-19-local-news/covid-19-canadian-company-testing-vaccine-candidates-that-target-variant-strains-3628843
